<DOC>
	<DOCNO>NCT00701753</DOCNO>
	<brief_summary>An individual 's genetic make-up know determine response antipsychotic medication . Genetic marker determine efficacy side effect medication may identify use predict treatment outcome . The study naturalistic study routinely prescribe antipsychotic use outcome measure undertaken part routine clinical care cohort . These clinical data link genetic information obtain DNA RNA blood sample undertake part study . No alteration make subject treatment regime medication . The study two stage investigation : - The first stage involve collection databank clinical information blood sample DNA RNA extraction patient treat antipsychotic medication . - The second stage molecular genetic investigation treatment-related genetic factor may contribute response prediction predisposition side effect . From genetic study pharmacogenetic prediction test validate and/or developed .</brief_summary>
	<brief_title>A Pharmacogenetic Investigation Antipsychotics Schizophrenia Schizophrenia-Like Psychoses</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Written informed consent must obtain DSMIV diagnosis must one : schizophrenia schizophreniform schizoaffective delusional disorder brief reactive psychosis psychosis otherwise specify Ethnic origin parent must know A minimum 6 week continuous treatment complete give antipsychotic , prescribe least minimum recommended dos Prospectively collect outcome data available ( pretreatment least 6 week treatment ) Exclusion criterion : Significant psychiatric medical comorbidity include history : head injury loss consciousness seizures neurological disorder mental retardation ( DSMIV ) drug alcohol dependence ( DSMIV ) serious physical illness e.g . malignancy , hepatic/renal insufficiency Concomitant psychotropic medication may influence rating Concomitant antipsychotic , antidepressant mood stabiliser prescribe &gt; 2 week antipsychotic treatment period rat</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Pharmacogenetic</keyword>
	<keyword>DNA</keyword>
	<keyword>RNA</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>Personalized medicine</keyword>
</DOC>